Bluebird bio, situated in Massachusetts, determined it was time for a new headquarters because many of its employees were working from home and others had gone for a new spinoff venture. A move from Kendall Square in Cambridge, three miles north, to Assembly Row in Somerville, along the Mystic River, would not only meet the firm’s changing needs, but will also save nearly $120 million in overhead over the next six years, according to the company.
“As we navigated through the COVID-19 epidemic and re-established ourselves as a firm focused on pursuing curative gene therapies over the last 18 months, we’ve revolutionised the way we work and live.” Bluebird, which is 11 years old, announced earlier this year that its oncology arm would be spun out as 2seventy bio. The spinoff was completed this week by the corporation. 2seventy bio is led by Bluebird previous CEO Nick Leschly, with Andrew Obenshain, the company’s former rare illness chief, taking over as the CEO of the company.